Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Receivables (2016 - 2025)

Historic Receivables for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $2.7 million.

  • CytomX Therapeutics' Receivables fell 3870.17% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 3870.17%. This contributed to the annual value of $4.2 million for FY2024, which is 2537.29% down from last year.
  • CytomX Therapeutics' Receivables amounted to $2.7 million in Q3 2025, which was down 3870.17% from $3.1 million recorded in Q2 2025.
  • CytomX Therapeutics' Receivables' 5-year high stood at $71.0 million during Q4 2022, with a 5-year trough of $1.6 million in Q1 2021.
  • For the 5-year period, CytomX Therapeutics' Receivables averaged around $7.7 million, with its median value being $3.1 million (2025).
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 9925.91% in 2021, then skyrocketed by 436452.83% in 2022.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Receivables stood at $1.6 million in 2021, then soared by 4364.53% to $71.0 million in 2022, then crashed by 92.07% to $5.6 million in 2023, then fell by 25.37% to $4.2 million in 2024, then crashed by 35.07% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $3.1 million for Q2 2025, and $3.0 million during Q1 2025.